| May-17-19 09:05AM | Rigel Initiates Enrollment in Pivotal Blood Disorder Study Zacks |
| May-16-19 08:00AM | AstraZeneca Continues to Redefine Cancer Treatment at The 2019 ASCO Annual Meeting Business Wire |
| May-15-19 09:07AM | 3 Top Diabetes Stocks to Watch in May Motley Fool |
| May-14-19 11:51AM | AstraZeneca Needs New Breast Cancer Drug to be Blockbuster GuruFocus.com |
| May-11-19 02:51AM | AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks |
| May-10-19 03:29PM | AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark Zacks |
| 10:21AM | Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates Zacks |
| 07:34AM | Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug Zacks |
| May-09-19 12:14PM | Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch |
| 01:30AM | AstraZeneca Gets an $8 Billion Punishment Bloomberg |
| May-08-19 09:46AM | Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong Zacks |
| 07:00AM | AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Cancer Business Wire |
| May-07-19 10:53AM | Guardant Health (GH) to Report Q1 Earnings: What's in Store? Zacks |
| May-03-19 09:00AM | Change Makers Across the Oncology Community Recognized at 2019 Cancer Community (C2) Awards Business Wire |
| 08:36AM | Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall Zacks |
| May-02-19 11:47AM | Edited Transcript of AZN.L earnings conference call or presentation 26-Apr-19 11:00am GMT Thomson Reuters StreetEvents |
| 08:16AM | The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga |
| 03:05AM | AstraZeneca ties up with France's Transgene to develop viral immunotherapies Reuters |
| May-01-19 08:50AM | BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery TechCrunch |
| 02:23AM | An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Suggests It's 46% Undervalued Simply Wall St. |
| Apr-30-19 01:00PM | Health Care Stocks: Buy Them While They're Down Kiplinger |
| 11:39AM | AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? Zacks |
| 09:48AM | Merck (MRK) Beats on Q1 Earnings & Sales as Keytruda Shines Zacks |
| Apr-29-19 05:08PM | Better Big Pharma Stock: AbbVie vs. AstraZeneca Motley Fool |
| 02:20PM | Md. biotech files to go public in up to $92M offering American City Business Journals |
| Apr-26-19 06:31PM | AstraZeneca PLC (AZN) Q1 2019 Earnings Call Transcript Motley Fool |
| 04:20PM | This Drug Giant Nearly Doubled Its Earnings So Why Are Shares Slipping? Investor's Business Daily |
| 11:13AM | This Drug Giant Nearly Doubled Its Earnings So Why Are Shares Slipping? Investor's Business Daily |
| 10:59AM | AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales Zacks |
| 09:29AM | Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales Zacks |
| 09:23AM | AstraZeneca, RBS earnings weigh on London markets MarketWatch |
| 06:45AM | Newer drugs fuel AstraZeneca quarterly sales beat Reuters |
| 05:41AM | AstraZeneca's first quarter profits jump 74% Associated Press |
| 05:41AM | Astrazeneca: 1Q Earnings Snapshot Associated Press |
| 05:26AM | AstraZeneca first-quarter sales beat estimates on cancer drugs Reuters |
| 03:58AM | AstraZeneca first-quarter sales beat estimates on cancer drugs Reuters |
| 03:20AM | AstraZeneca Cancer Drug Sales Fuel Profit Beating Estimates Bloomberg |
| 02:56AM | AstraZeneca cancer drugs drive growth in sales Financial Times |
| Apr-25-19 09:55AM | Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y Zacks |
| Apr-24-19 12:00AM | AstraZeneca chief claims vindication five years after Pfizer bid Financial Times |
| Apr-23-19 10:44AM | What's in the Cards for AstraZeneca (AZN) in Q1 Earnings? Zacks |
| Apr-18-19 09:38AM | AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why Zacks |
| Apr-17-19 11:06AM | Top Ranked Income Stocks to Buy for April 17th Zacks |
| Apr-15-19 09:57AM | Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks |
| 05:28AM | London's FTSE 100 tugged down by miners; IWG lifts midcaps Reuters |
| Apr-12-19 10:30AM | Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks |
| 09:55AM | Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall Zacks |
| Apr-10-19 03:24PM | Here's what to expect from the stock market next month Investopedia |
| 11:11AM | Is AstraZeneca Stock Worth Buying Before Earnings? InvestorPlace |
| 10:46AM | Alkermes Reports Positive Data From Schizophrenia Study Zacks |
| 10:20AM | J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store? Zacks |
| 10:14AM | AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks |
| Apr-09-19 11:24AM | PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 Zacks |
| 10:30AM | Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457 Zacks |
| Apr-08-19 09:41AM | The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca Zacks |
| 03:04AM | Is AstraZeneca PLC's (LON:AZN) Balance Sheet A Threat To Its Future? Simply Wall St. |
| Apr-07-19 10:33PM | City of London alarmed at EUs no-deal Brexit equity trading plan Financial Times |
| Apr-06-19 03:41AM | Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks |
| Apr-05-19 09:26PM | Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men Zacks |
| 10:34AM | Will Ironwood Suffer From Dependence on Linzess' Progress? Zacks |
| 10:20AM | Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU Zacks |
| 09:33AM | Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck Zacks |
| 01:15AM | Investors Chronicle: Hostelworld. YouGov, AstraZeneca Financial Times |
| Apr-04-19 10:36AM | Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks |
| Apr-03-19 10:22AM | Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks |
| 07:23AM | Daiichi Sankyo Company, Limited -- Moody's: Daiichi Sankyo's collaboration with AstraZeneca is positive for the former's oncology franchise Moody's |
| Apr-02-19 11:15AM | AstraZeneca May Not Have the Cash Flow to Pull Off Its Big Expansion Barrons.com |
| 10:04AM | Merck's Keytruda Gets Nod for First-Line Lung Cancer in China Zacks |
| 09:44AM | Advaxis Up on Positive Early-Stage Immunotherapy Study Data Zacks |
| 06:53AM | Stocks to watch: Rolls-Royce, Lyft, AstraZeneca, Fevertree, Pandora Financial Times |
| 06:32AM | Zeneca Wilmington Inc. -- Moody's changes outlook on AstraZeneca's A3 ratings to stable; affirms ratings Moody's |
| Apr-01-19 03:36PM | AstraZeneca's Selumetinib Gets Breakthrough Therapy Status Zacks |
| 12:12PM | The Dow Is Gaining Because Good News From China Is Good News for Stocks Barrons.com |
| 11:19AM | AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation Benzinga |
| 06:30AM | Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1 Business Wire |
| Mar-29-19 04:47PM | AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA Zacks -5.93% |
| 04:33PM | Why AstraZeneca, Yeti Holdings, and CannTrust Holdings Slumped Today Motley Fool |
| 01:41PM | FTSE 100 gains as trade progress offsets latest Brexit setback Reuters |
| 12:48PM | AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo Zacks |
| 11:30AM | Japan's Daiichi Strikes Cancer Therapy Deal With AstraZeneca Worth Up To $6.9B Benzinga |
| 10:42AM | Mondelez may be shopping, AstraZeneca makes major deal, Tim Cook may testify Yahoo Finance |
| 10:34AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 10:19AM | Mondelez may be shopping, AstraZeneca makes major deal, Tim Cook may testify Yahoo Finance Video |
| 09:28AM | AstraZeneca in cancer deal with Daiichi Sankyo Associated Press |
| 09:10AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 09:06AM | RH Stock Tumbles, AstraZeneca Slides and 3 More Friday Morning Movers Barrons.com |
| 08:42AM | AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal Reuters |
| 08:16AM | AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo TheStreet.com |
| 08:10AM | Stocks to watch: AstraZeneca, Tui, H&M, Auto Trader, Jupiter, Evraz Financial Times |
| 08:06AM | Is This a Drug Deal or a Rights Offering? Bloomberg |
| 06:43AM | AstraZeneca Bets $6.9 Billion in Japan Cancer Therapy Deal Bloomberg |
| 03:51AM | Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps Reuters |
| 12:46AM | AstraZeneca in $6.9bn cancer deal with Daiichi Sankyo Financial Times |
| Mar-28-19 08:08PM | AstraZeneca and Daiichi Sankyo to jointly develop cancer drug Reuters |
| 01:29PM | European shares give up gains as banks weigh amid concerns on growth, Brexit Reuters |
| 10:43AM | AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes Zacks |
| 04:44AM | There's a feeling of 'deep uncertainty': AstraZeneca CNBC Videos |
| Mar-27-19 05:39PM | Calithera (CALA) Initiates Phase I/II Study of Telaglenastat Zacks |
| 05:09PM | Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge Zacks |
| Mar-26-19 08:15PM | Were Hedge Funds Right About AstraZeneca plc (AZN)? Insider Monkey |
|
|
|
| AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a collaboration and license option agreement with Transgene SA for clinical development and commercialization of novel oncolytic immunotherapies. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. |
